Drug Database
SP

spironolactone (Spiroderm)

✓ Approved

Merck KGaA · NR3C2 · 小分子

什么是 spironolactone?

spironolactone 是一种小分子,由Merck KGaA研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名Spiroderm
公司Merck KGaA
药物类别小分子
分子靶点NR3C2, SCNN1A
给药途径Topical
状态Approved

作用机制

分子靶点

spironolactone 作用于 2 个分子靶点:

NR3C2nuclear receptor subfamily 3 group C member 2 (NR3C2VIT, MR)
SCNN1Asodium channel epithelial 1 subunit alpha (SCNEA, BESC2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

spironolactone 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Skin and subcutaneous tissue disordersAcne✓ Approved

相关研究文献

PubMedExpert opinion on drug delivery2026-11-19

Dissolving and hydrogel-based polymeric microneedles for bacterial keratitis: materials, therapeutic payloads, design-performance relationships, and future perspectives.

Peirovi Babak B, Amanzadi Bentolhoda B, Censi Roberta R, Aghamollaei Hossein H

Bacterial keratitis (BK) is a major cause of corneal visual impairment. Although topical antibiotics remain the mainstay of treatment, tear turnover, blinking, nasolacrimal drainage, and the corneal epithelial barrier limit drug residence and penetration. Polymeric microneedles, particularly dissolving and hydrogel-based systems, may enhance ocular residence of therapeutic agents and enable controlled or sustained drug release. This review summarizes corneal anatomy and ocular drug-delivery barriers, outlines the pathophysiology of bacterial keratitis, and evaluates microneedle platforms developed for ocular applications, with emphasis on dissolving and hydrogel-based polymeric systems for bacterial keratitis. A focused search of PubMed, Scopus, and ScienceDirect was undertaken, supplemented by a search of Google Scholar to identify additional relevant studies. Relevant studies were compared according to polymer composition, microneedle dimensions and density, penetration depth, dissolution or swelling, and release kinetics. Polymer design-property relationships, including the effects of concentration, molecular weight, crosslinking, biodegradability, and post-administration polymer fate, are also discussed. Polymeric microneedles offer a promising strategy for overcoming corneal delivery barriers, but clinical translation will depend on reproducible manufacturing, mechanical and ocular safety, sterilization and storage stability, user-friendly application, and robust clinical evidence demonstrating advantages over optimized topical therapies.

PMID 43053713
阅读全文 →
PubMedCell death discovery2026-11-19

CaMK4 drives pathogenic Th17 cell response via the STAT3/RORγt axis in psoriasis.

Ge Huiyao H, Zhang Xinwen X, Chen Mei M, Ren Yan Y et al.

Psoriasis is a chronic inflammatory skin disease driven by dysregulated immune responses, particularly those mediated by pathogenic Th17 cell response; however, the key intracellular signaling molecules that specifically regulate Th17 cell pathogenicity in the skin remain incompletely defined. Here, we showed that CaMK4 was highly expressed in CD4+ T cells from psoriatic lesional skin in both humans and mice. T cell-specific Camk4 deletion alleviated imiquimod (IMQ)-induced psoriasiform dermatitis, accompanied by reduced epidermal hyperplasia and decreased frequencies of skin RORγt⁺ and IL-17A⁺ CD4⁺ T cells. Mechanistically, CaMK4 mediated IL-23-triggered phosphorylation of STAT3, which promoted the expression of RORγt and IL-17A in CD4⁺ T cells. In vivo, reconstitution of STAT3 activity restored psoriasiform dermatitis in T cell-specific Camk4-deficient mice. Furthermore, topical application of a CaMK4 inhibitor ameliorated IMQ-induced skin pathology. Clinically, CAMK4 expression positively correlated with RORC and IL17A levels in CD4⁺ T cells from psoriasis patients, and inhibition of CaMK4 suppressed IL-23-induced Th17 cell response both in patient-derived CD4⁺ T cells and in ex vivo human skin explants. These findings identify CaMK4 as a critical driver of pathogenic Th17 cell response via the STAT3/RORγt axis in psoriasis and suggest that it may represent a potential target for further therapeutic exploration.

PMID 43052244
阅读全文 →
PubMedAesthetic surgery journal2026-11-19

Determining the Appropriate Age for Aesthetic Procedures in Minors: A Review of the Guidelines, Outcomes, and Ethical Considerations.

Gimenez Lynch Carlota C, Munkwitz Sara E SE, Smith Kierstyn K, Shah Hana H et al.

Adolescents seeking aesthetic procedures present unique clinical and ethical challenges because they exist within an evolving stage of cognitive, emotional, and physical development. Although legal frameworks generally require parental consent for minors, determining procedural appropriateness extends beyond consent alone. It also requires careful consideration of psychosocial maturity, motivation, and long-term well-being. Perspectives regarding cosmetic procedures in minors vary widely, particularly because many interventions are performed to improve appearance or psychosocial distress rather than treat a clearly defined medical condition. This review synthesizes current evidence regarding regulatory considerations, safety outcomes, and ethical principles surrounding non-surgical and surgical aesthetic procedures in minors. Common non-surgical procedures include topical skincare regimens, injectables, lasers, skin resurfacing, and microneedling. Commonly performed surgical procedures include otoplasty, rhinoplasty, breast reduction, breast augmentation, and other body contouring interventions. Throughout the literature, there is substantial variability in minimum age recommendations, professional guidance, and procedural oversight across procedures and countries. However, prior studies have generally demonstrated favorable safety profiles, high postoperative satisfaction, and psychosocial improvement in appropriately selected adolescent patients. Given the absence of standardized age requirements for many procedures, surgeons bear substantial responsibility in determining procedural appropriateness on an individualized basis. Careful assessment of emotional maturity, body image, social influences, motivation, and understanding of procedural risks and limitations is therefore critical when evaluating minors seeking aesthetic intervention.

PMID 43053604
阅读全文 →
PubMedDermatology online journal2026-11-18

Treating hair loss related to pregnancy and lactation: A literature review.

Maas Derek D, Zaminski Devyn D, Bawany Fatima F, Brown Claire C et al.

Hair quality and quantity can be negatively affected during pregnancy and the postpartum period, including lactation, and the psychosocial effects can be profound. Common causes of hair loss in this period are androgenetic alopecia (AGA) and telogen effluvium (TE), which may be exacerbated by stress and hormonal shifts. To assess the safety of hair-targeted pharmacotherapies for AGA and TE during pregnancy and lactation. Guidelines from the United States Food and Drug Administration, Briggs Drugs in Pregnancy and Lactation, the American Academy of Pediatrics, Hale's Medications & Mothers' Milk, and the National Library of Medicine's Drugs and Lactation Database (LactMed) were reviewed. Additionally, relevant articles were identified through PubMed using a combination of keywords, including treatment names, "hair loss," "alopecia," "pregnancy," "lactation," and "breastfeeding." Topical minoxidil, oral spironolactone, and topical tretinoin may be used for AGA (and TE for topical minoxidil) during lactation, but not during pregnancy. Ketoconazole 2% shampoo is recommended for AGA in pregnancy or lactation but is unlikely to be effective for TE. Platelet-rich plasma (PRP) injections may be considered for AGA or TE during pregnancy or lactation, but all 5-alpha reductase inhibitors (5-ARIs) or supplements with 5-ARI activity should be avoided. Vitamin D and iron supplements are recommended when deficiencies are present. Hair loss during pregnancy and lactation is common and, despite often being temporary, can have a substantial psychosocial impact on quality of life and well-being. Several therapies may be considered, including topical treatments, supplements, and PRP, while others are not recommended owing to safety concerns or insufficient evidence.

PMID 43048788
阅读全文 →
PubMedJFMS open reports2026-11-18

Use of subconjunctival cyclosporine implants for treatment of feline eosinophilic keratoconjunctivitis: A case report.

Willems Lynn L, Roberts Jordan K JK

A 5-year-old, neutered male domestic shorthair cat was presented for evaluation of chronic bilateral eosinophilic keratoconjunctivitis (EK). The patient had a history of recurrent corneal plaques and conjunctivitis that were initially managed with systemic and topical immunosuppressive therapy. Long-term disease control was limited by poor tolerance of topical ophthalmic medications, resulting in inconsistent treatment and repeated disease recurrence affecting both eyes. Over several years, the cat was treated with subconjunctival triamcinolone acetonide, antiviral therapy, and topical megestrol acetate, with only partial and temporary improvement. As a result of persistent disease and inability to administer long-term topical therapy reliably, bilateral subconjunctival cyclosporine implants were surgically placed. Postoperative management included short-term topical antibiotic therapy. At 10-week and 7-month postoperative examinations, marked clinical improvement was observed, with resolution of most corneal plaques and substantial reduction in conjunctival inflammation. Feline EK is a chronic immune-mediated ocular surface disease that typically requires long-term topical immunosuppressive therapy. Successful management may be limited in patients who are resistant to medication administration. This case demonstrates that subconjunctival cyclosporine implants may represent a viable long-acting treatment option for feline EK when topical therapy cannot be consistently administered. To the authors' knowledge, the use of cyclosporine implants for the management of feline EK has not previously been reported.

PMID 43048052
阅读全文 →
PubMedJournal of cosmetic dermatology2026-11-18

Low-Dose Oral Versus Topical Minoxidil in Androgenetic Alopecia: A Randomized, Double-Blind, Double-Dummy Controlled Trial.

Chaudhry Muhammad Asad Ejaz MAE, Muneeb Bushra B, Aamir Safoora S, Saeed Zoha Arif ZA et al.

Androgenetic alopecia (AGA) is a prevalent, progressive condition with significant psychosocial impact. Current pharmacological modalities like topical minoxidil and finasteride have limitations. Low-dose oral minoxidil has surfaced as a valid off-label solution, with the practical advantage of once-daily dosing. To evaluate the efficacy and safety of topical and oral minoxidil in AGA. In this double-blind, double-dummy randomized controlled trial, 100 patients aged 18-50 years with AGA were randomized to receive either twice-daily topical minoxidil (5% in males, 2% in females) plus a placebo tablet, or once-daily oral minoxidil (2.5 mg in males, 1.25 mg in females) plus a placebo spray for 6 months. The primary outcome was the proportion of patients achieving ≥ +1 improvement in a validated 7-point global photographic scale. Secondary outcomes included patient satisfaction and adverse effects. Data were analyzed using SPSS v26 with p ≤ 0.05 as significant. Ninety patients completed 24 weeks of follow-up. Photographic assessment demonstrated that mild-to-excellent improvement (≥ +1) occurred in both the oral (67%) and topical minoxidil (73%) groups (p = 0.652). Patient-reported satisfaction was high in both groups (topical: 70.5%; oral: 80.4%, p = 0.332), with a non-significant trend favoring oral minoxidil at the moderate satisfaction threshold (58.7% vs. 38.6%, p = 0.057). Median improvement scores were comparable between groups for both clinician assessment and patient-reported outcomes. Hypertrichosis was significantly more frequent with oral minoxidil (30% vs. 9%, p = 0.011), whereas contact dermatitis was exclusive to topical minoxidil (11% vs. 0%, p = 0.025). No serious adverse events were observed. Both topical and low-dose oral minoxidil demonstrated clinically meaningful improvement in androgenetic alopecia. Despite oral therapy exhibiting a trend toward higher patient satisfaction, this study was not powered to establish non-inferiority or equivalence. The dermatologist-assessed outcomes indicated no significant intergroup differences. Low-dose oral minoxidil may be considered a practical alternative in selected patients, particularly where adherence to topical therapy is limited. ClinicalTrials.gov: NCT07273799.

PMID 43047224
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多spironolactone